Overview

Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in Anew Kidney Transplant Patients

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
To investigate the efficacy and safety of ATG-F induction regimen using a single dose of ATG-F compared with a five-day dose regimen of ATG-F in anew kidney transplant recipients.
Phase:
Phase 4
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Antibodies
Antilymphocyte Serum
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin